Phase 2 × Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Phase 2 Terminated
14 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
PONS
Phase 2 Terminated
18 enrolled
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2 Terminated
12 enrolled 8 charts
T-cell Depleted Alternative Donor Transplantation
Phase 2 Terminated
53 enrolled 14 charts
AFR22
Phase 2 Terminated
19 enrolled 4 charts
MACS0254
Phase 2 Terminated
18 enrolled 12 charts
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Phase 2 Terminated
27 enrolled 14 charts
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
7 enrolled
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase 2 Terminated
7 enrolled 5 charts
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Phase 2 Terminated
1 enrolled
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Phase 2 Terminated
117 enrolled 6 charts
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Phase 2 Terminated
9 enrolled 13 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Phase 2 Terminated
36 enrolled
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Phase 2 Terminated
34 enrolled 12 charts
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
24 enrolled 6 charts
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
Phase 2 Terminated
5 enrolled 4 charts
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
Phase 2 Terminated
2 enrolled 3 charts
Haploid Allogeneic Transplant Using the CliniMACS System
Phase 2 Terminated
13 enrolled 7 charts
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Phase 2 Terminated
15 enrolled 6 charts
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Phase 2 Terminated
3 enrolled 6 charts
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
Phase 2 Terminated
6 enrolled
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Phase 2 Terminated
1 enrolled
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Phase 2 Terminated
52 enrolled 8 charts
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Phase 2 Terminated
13 enrolled 14 charts
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢
Phase 2 Terminated
40 enrolled
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts
Dasatinib
Phase 2 Terminated
50 enrolled
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Terminated
4 enrolled 7 charts
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
40 enrolled
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Terminated
48 enrolled
CML
Phase 2 Terminated
5 enrolled